|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | **Vigabatrine**  **n=129** | **Hormonotherapy**  **n=73** | **Combination Therapy n=78** | **p** |
| **Spasm cessation** | <14 days | 47(36.4%) | 36(49.3%) | 38(48.7%) | 0.73 |
| 14-42 days | 37(28.7%) | 23(31.5%) | 24(30.8%) |
| >42 days | 45(34.9%) | 14(19.2%) | 16(20.5%) |
| **Resolution of hypsarrhythmia** | <1 months | 30(23.3%) | 28(38.4%) | 25(32.1%) | 0.245 |
| 1-3 months | 49(38%) | 23(31.5%) | 27(34.6%) |
| >3 months | 50(38.8%) | 22(30.1%) | 26(30.3%) |
| **Relaps** | Yes | 30(23.2%) | 15(20.5%) | 18(23.1%) | 0.254 |
| No | 99(76.7%) | 58(79.5%) | 60(76.9%) |
| **Evolution of different epileptic syndrome\*** | Yes \* | 64(49.6%) | 43(58.9%) | 40(51.3%) | 0.562 |
| No | 65(50.4%) | 30(41.1%) | 38(48.7%) |
| **Etiology specific subgroups** | Structural | 64(49.6%) | 35(47.9%) | 36(46.2%) | 0.703 |
| Genetic\* | 9 (7%) | 6(8.2%) | 9(11.5%) |
| Immun /Infectious | 5(3.9%) | 2(2.7%) | 3(3.8%) |
| Metabolic | 9(7%) | 1(1.4%) | 3(3.8%) |
| Unknown | 42(32.6%) | 29(39.7%) | 27(34.6%) |

**Table 1:** Comparison of treatment modalities in infantile spasm syndrome